Supercharge Your Innovation With Domain-Expert AI Agents!

Prophylactic or therapeutic drug for constipation

A constipation and pharmaceutical technology, applied in the direction of drug combination, pharmaceutical formula, preparation for in vivo test, etc., can solve the problem of unknown constipation prevention or treatment effect, etc., and achieve the effect of stable effect, chemical stability and less side effects

Inactive Publication Date: 2015-09-30
TAISHO PHARMACEUTICAL CO LTD
View PDF19 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, for these compounds that inhibit SGLT1, the preventive or therapeutic effect of constipation is unknown

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Prophylactic or therapeutic drug for constipation
  • Prophylactic or therapeutic drug for constipation
  • Prophylactic or therapeutic drug for constipation

Examples

Experimental program
Comparison scheme
Effect test

reference example 1

[0131] Manufacture of compound (I)

[0132] Step 1: Fabrication of compound 3

[0133] In a solution of compound 1 (95.0g, 281mmol) in tetrahydrofuran (1395mL), under an argon atmosphere, a n-butyllithium hexane solution (2.66M, 111mL) was added dropwise at -75 to -72°C for 45 minutes. Stir at 75~-72°C for 33 minutes. Next, a solution of compound 2 (138 g, 295 mmol) in tetrahydrofuran (400 mL) was added dropwise at -78 to -73°C over 1 hour and 37 minutes, and stirred at -76 to -73°C for 20 minutes. Next, trimethylchlorosilane (32.1 g, 295 mmol) was added dropwise at -76 to -73°C over 5 minutes, followed by stirring at -76 to -73°C for 1 hour and 15 minutes. Next, n-butyllithium hexane solution (2.66 M, 153 mL) was added dropwise at -76 to -72°C over 1 hour and 5 minutes, followed by stirring at -76 to -72°C for 20 minutes. Next, a solution of 4-bromobenzaldehyde (57.2 g, 309 mmol) in tetrahydrofuran (400 mL) was added dropwise at -75 to -72°C over 1 hour and 5 minutes, foll...

reference example 2

[0139] Step 2: Fabrication of Compound 4

[0140] Acetic anhydride (12.8 mL) was added to a solution of compound 3 (8.92 g) in pyridine (30.0 mL), followed by stirring at 22 to 27° C. for 23 hours and 40 minutes. The reaction solution was cooled in an ice-water bath, water (30.0 mL) was added, and after stirring for 10 minutes, toluene (50.0 mL) was added. After separating into an organic layer and an aqueous layer, the aqueous layer was extracted with toluene (50.0 mL), and separated into an organic layer and an aqueous layer. The combined organic layers were washed three times with 2M hydrochloric acid (50.0 mL), followed by saturated aqueous sodium bicarbonate (50.0 mL) and saturated aqueous sodium chloride (50.0 mL), and separated into an organic layer and an aqueous layer. After the organic layer was dried over anhydrous magnesium sulfate (7.02 g), the solvent was distilled off under reduced pressure, followed by drying under reduced pressure to obtain a crude product (1...

reference example 3

[0148] Step 3: Fabrication of compound 5

[0149] Tert-butyldimethylsilane (6.07 g) and water (0.235 mL) were added to a solution of compound 4 (9.62 g) in acetonitrile (96.0 mL), and cooled with an ice-water bath. Trimethylsilyl trifluoromethanesulfonate (10.1 mL) was added dropwise to the mixture over 13 minutes at 1 to 7°C, followed by stirring at 5 to 11°C for 1 hour and 15 minutes. Toluene (100 mL) was added to the reaction liquid, and the mixture was washed twice with 3% aqueous sodium bicarbonate (50.0 mL). After the organic layer was distilled off under reduced pressure, the residue was dried under reduced pressure to obtain a colorless amorphous crude product (9.29 g). The crude product was treated with silica gel column chromatography [using hexane: ethyl acetate = 2:1, 1:1 (v / v), ethyl acetate to elute sequentially] to obtain compound 5 (1.12g) as a colorless powder .

[0150]

[0151]

[0152]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided is a novel therapeutic drug that is useful in preventing or treating constipation, said drug comprising a compound capable of inhibiting SGLT1, in particular, a 4-isopropylphenyl glucitol compound represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.

Description

technical field [0001] The present invention relates to a preventive or therapeutic drug for constipation, and more specifically, to a drug for constipation that contains a compound that inhibits sodium-dependent glucose cotransporter 1 (sodium-dependent glucose cotransporter 1, hereinafter sometimes referred to as SGLT1) as an active ingredient. Preventive or therapeutic medicine. Background technique [0002] Constipation and constipation refer to a state in which the frequency and volume of defecation are reduced, accompanied by pain or difficulty in excretion of stool. The frequency of constipation is presumed to be increasing due to changes in dietary habits, lack of exercise, time-constrained and stressful social life, and aging of the population. [0003] In a normal state, at the end of digestion and absorption of ingested food, intestinal contents that become indigestible matter are transported from the small intestine to the large intestine. The water in the larg...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/351A61P1/10A61P43/00C07D309/10
CPCA61K9/2059C07D309/10A61K31/351A61K9/1652A61K31/7034A61P1/10A61P43/00A61K2123/00A61K2121/00
Inventor 山本大辅井尾房代山本浩二
Owner TAISHO PHARMACEUTICAL CO LTD
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More